No Data
Cube Pharmaceuticals: Report for the third quarter of 2024
Hefei Lifeon Pharmaceutical (003020.SZ) released its performance for the first three quarters, with a net income of 0.119 billion yuan, a year-on-year decrease of 30.57%.
Hefei Lifeon Pharmaceutical (003020.SZ) released its 2024 third quarter report. In the first three quarters, the company achieved revenue...
Hefei Lifeon Pharmaceutical (003020.SZ): The net income in the first three quarters was 0.119 billion yuan, a year-on-year decrease of 30.57%.
On October 29, Gelonhui reported that Hefei Lifeon Pharmaceutical (003020.SZ) announced its third quarter report for 2024, achieving revenue of 1.125 billion yuan in the first three quarters, a decrease of 26.20% year-on-year; net income attributable to shareholders of the listed company was 0.119 billion yuan, a decrease of 30.57% year-on-year; net profit attributable to shareholders of the listed company excluding non-recurring gains and losses was 0.112 billion yuan, a decrease of 24.10% year-on-year; basic earnings per share 0.63 yuan.
Hefei Lifeon Pharmaceutical (003020.SZ): received the acceptance notification of the application for the listing of Ivabradine Hydrochloride active pharmaceutical ingredient.
Hefei Lifeon Pharmaceutical (003020.SZ) announced on October 18th that the company has recently received the "Acceptance Notice" for the market application of Ivabradine Hydrochloride active pharmaceutical ingredient issued by the National Medical Products Administration. Ivabradine Hydrochloride is a drug that simply lowers heart rate. Its formulation is suitable for patients with sinus rhythm and heart rate ≥75 beats/minute, accompanied by heart contraction dysfunction of NYHA II-IV chronic heart failure, and is used in combination with standard treatment including beta-blockers, or when beta-blockers are contraindicated or intolerable. Currently, in addition to the company, there are five other enterprises in China registered for this product.
Hefei Lifeon Pharmaceutical Pain Medication 40mg Dosage Gets NMPA's Nod
hefei lifeon pharmaceutical (003020.SZ): Hydroxybutylate hydrochloride sustained-release tablets 40mg specifications approved.
On October 11, Gelonghui reported that Hefei Lifeon Pharmaceutical (003020.SZ) announced that recently, Hefei Lifeon Pharmaceutical Co., Ltd. received the 'Drug Supplementary Application Approval Notice' for Hydrocodone Hydrochloride Controlled-Release Tablets issued by the National Medical Products Administration. The product was approved for the following supplementary application items: adding specifications: Hydrocodone Hydrochloride Controlled-Release Tablets (40mg), issuing a drug approval number, attaching the revised quality standards, packaging labels, instructions, and production process photos. The original research and development company of Hydrocodone Hydrochloride Controlled-Release Tablets is PURDUE PHARMA LP, mainly used clinically to relieve persistent moderate pain.
Investors Don't See Light At End Of Hefei Lifeon Pharmaceutical Co., Ltd.'s (SZSE:003020) Tunnel And Push Stock Down 27%No Data
No Data
